Nakazawa Toru, Tomita Hiroshi, Yamaguchi Katsuhiro, Sato Yumi, Shimura Masahiko, Kuwahara Soichiro, Tamai Makoto
Department of Ophthalmology, Tohoku University School of Medicine, Sendai, Japan.
Curr Eye Res. 2002 Feb;24(2):114-22. doi: 10.1076/ceyr.24.2.114.8162.
To determine whether nipradilol, a new anti-glaucoma drug, can protect retinal ganglion cells (RGCs) from secondary cell death caused by transection of the optic nerve (ON).
The ON was transected 0.7 mm from its exit from the eye in Sprague Dawley rats. Nipradilol (1 x 10(-8) - 10(-3) M), timolol, prazosin, or sodium nitroprusside (SNP) (1 x 10(-6) - 10(-4) M) was injected intravitreally fifteen-minutes before the ON transection. Control eyes received the same amount of phosphate buffered (PB). The RGCs were labeled retrogradely by placing gelfoam soaked in fluoro-gold (FG) on the stump of ON. RGCs density was determined by counting the FG-labeled RGCs in flat-mounted retinas 3 to 14 days post-transection. To determine whether the neuroprotective action of nipradilol was due to its NO-donor property, carboxy-PTIO, a NO-scavenger, or KT5832, a protein kinase G inhibitor, was injected with the nipradilol.
After ON transection, the number of surviving RGCs after intravitreal injection of 1 x 10(-4) M nipradilol was significantly higher than that following PB injection. This protective activity was dose-dependent. Neither timolol nor prazosin had a neuroprotective effect but SNP protected RGCs in a dose-dependent manner. Carboxy-PTIO and KT5832 decreased the neuroprotective effect of nipradilol.
These results indicate that nipradilol has a possibility of neuroprotective effect on axotomized RGCs, and the effect depended mainly on its NO-donor property.
确定新型抗青光眼药物尼普地洛是否能保护视网膜神经节细胞(RGCs)免受视神经横断所致的继发性细胞死亡。
在Sprague Dawley大鼠中,将视神经从眼球出口处切断0.7毫米。在视神经横断前15分钟,玻璃体腔内注射尼普地洛(1×10⁻⁸ - 10⁻³ M)、噻吗洛尔、哌唑嗪或硝普钠(SNP)(1×10⁻⁶ - 10⁻⁴ M)。对照眼注射等量的磷酸盐缓冲液(PB)。通过将浸泡在荧光金(FG)中的明胶海绵置于视神经残端,对RGCs进行逆行标记。在横断后3至14天,通过计数平铺视网膜中FG标记的RGCs来确定RGCs密度。为了确定尼普地洛的神经保护作用是否归因于其NO供体特性,将NO清除剂羧基-PTIO或蛋白激酶G抑制剂KT5832与尼普地洛一起注射。
视神经横断后,玻璃体腔内注射1×10⁻⁴ M尼普地洛后存活的RGCs数量显著高于注射PB后的数量。这种保护活性呈剂量依赖性。噻吗洛尔和哌唑嗪均无神经保护作用,但SNP以剂量依赖性方式保护RGCs。羧基-PTIO和KT5832降低了尼普地洛的神经保护作用。
这些结果表明,尼普地洛有可能对视神经切断后的RGCs具有神经保护作用,且该作用主要取决于其NO供体特性。